Abstract
K+ Channels form the largest family among ion channels. Besides regulating many physiological functions, K+ channels, being aberrantly expressed in different types of tumors, affect several hallmarks of cancer. In cancer cells, K+ channel activity regulates cell proliferation, resistance to apoptotic cell death, tumor angiogenesis, invasiveness and metastatic spread. Moreover, being expressed in cells of the tumor microenvironment, K+ channels can also modulate the immune/inflammatory response which contributes to drive cancer establishment and progression. After almost 30 years of studies, some K+ channels are emerging as novel cancer biomarkers, to be employed to stratify patients for either prognostic or predictive purposes. Moreover, it is not remote the time in which it will be possible to target specific K+ channels in cancer for therapeutic purposes. One hindrance for applying a K+ channel-based therapy to cancer is the fact that K+ channel blockers can cause side effects, which often overlap with, but can mask, benefits. We here show some strategies to overcome harmful side effects caused by blocking K+ channels. Once taken into account these strategies, K+ channels may represent suitable and easily accessible cancer biomarkers and targets for therapy. The relevant patents related to K+ channels and cancer are discussed.
Keywords: Cancer biomarkers, cancer therapy, hallmarks of cancer, ion channel pharmacology, K+ channels, KV 11.1
Recent Patents on Anti-Cancer Drug Discovery
Title:Potassium Channels: Novel Emerging Biomarkers and Targets for Therapy in Cancer
Volume: 8 Issue: 1
Author(s): Massimo D’Amico, Luca Gasparoli and Annarosa Arcangeli
Affiliation:
Keywords: Cancer biomarkers, cancer therapy, hallmarks of cancer, ion channel pharmacology, K+ channels, KV 11.1
Abstract: K+ Channels form the largest family among ion channels. Besides regulating many physiological functions, K+ channels, being aberrantly expressed in different types of tumors, affect several hallmarks of cancer. In cancer cells, K+ channel activity regulates cell proliferation, resistance to apoptotic cell death, tumor angiogenesis, invasiveness and metastatic spread. Moreover, being expressed in cells of the tumor microenvironment, K+ channels can also modulate the immune/inflammatory response which contributes to drive cancer establishment and progression. After almost 30 years of studies, some K+ channels are emerging as novel cancer biomarkers, to be employed to stratify patients for either prognostic or predictive purposes. Moreover, it is not remote the time in which it will be possible to target specific K+ channels in cancer for therapeutic purposes. One hindrance for applying a K+ channel-based therapy to cancer is the fact that K+ channel blockers can cause side effects, which often overlap with, but can mask, benefits. We here show some strategies to overcome harmful side effects caused by blocking K+ channels. Once taken into account these strategies, K+ channels may represent suitable and easily accessible cancer biomarkers and targets for therapy. The relevant patents related to K+ channels and cancer are discussed.
Export Options
About this article
Cite this article as:
D’Amico Massimo, Gasparoli Luca and Arcangeli Annarosa, Potassium Channels: Novel Emerging Biomarkers and Targets for Therapy in Cancer, Recent Patents on Anti-Cancer Drug Discovery 2013; 8 (1) . https://dx.doi.org/10.2174/1574892811308010053
DOI https://dx.doi.org/10.2174/1574892811308010053 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Technetium-99m-based Radiopharmaceuticals in Sentinel Lymph Node Biopsy: Gynecologic Oncology Perspective
Current Pharmaceutical Design Stem Cell Therapies
Recent Patents on Regenerative Medicine The Influence of Salinomycin on the Expression Profile of mRNAs Encoding Selected Caspases and MiRNAs Regulating their Expression in Endometrial Cancer Cell Line
Current Pharmaceutical Biotechnology Relaxin: New Functions for an Old Peptide
Current Protein & Peptide Science Antineoplastic Action of Growth Hormone-Releasing Hormone (GHRH) Antagonists
Recent Patents on Anti-Cancer Drug Discovery Inflammation and Antiangiogenesis in Cancer
Current Medicinal Chemistry Neurobiological Underpinnings of the Estrogen - Mood Relationship
Current Psychiatry Reviews Breast Cancer Chemoprevention: Current Perspectives
Current Enzyme Inhibition Ruthenium Antimetastatic Agents
Current Topics in Medicinal Chemistry Zinc Dependent Histone Deacetylase Inhibitors in Cancer Therapeutics: Recent Update
Current Medicinal Chemistry Anticoagulant Therapy in Pregnant Patients with Metabolic Syndrome: A Review
Current Pharmaceutical Biotechnology Telomerase Inhibitors as Anticancer Therapy
Current Medicinal Chemistry - Anti-Cancer Agents Structure-Based Approach for the Discovery of Novel Selective Estrogen Receptor Modulators
Current Medicinal Chemistry Endogenous Retroviruses in Domestic Animals
Current Genomics Antagonists of Growth Hormone-Releasing Hormone in Oncology
Combinatorial Chemistry & High Throughput Screening Tubulin-Independent Tau in Alzheimer’s Disease and Cancer: Implications for Disease Pathogenesis and Treatment
Current Alzheimer Research Signal Transduction Pathways of Inflammatory Gene Expressions and Therapeutic Implications
Current Pharmaceutical Design MicroRNA: The Potential Regulator of Endometrial Carcinogenesis
MicroRNA Using Pharmacologic Data to Plan Clinical Treatments for Patients with Peritoneal Surface Malignancy
Current Drug Discovery Technologies Adiponectin: A Key Player in Obesity Related Disorders
Current Pharmaceutical Design